Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine

Fukushima J Med Sci. 2022 Apr 8;68(1):67-70. doi: 10.5387/fms.2021-28. Epub 2022 Mar 4.

Abstract

This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants' work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p = 0.016 with t-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (p value=0.24 with t-test).

Keywords: BNT162b2 vaccination; COVID-19; IgG antibody against SARS-CoV-2 spike protein.

MeSH terms

  • Adult
  • Antibodies, Viral* / immunology
  • BNT162 Vaccine* / administration & dosage
  • BNT162 Vaccine* / immunology
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / immunology
  • COVID-19* / prevention & control
  • Female
  • Humans
  • Immunoglobulin G* / immunology
  • Male
  • Middle Aged
  • SARS-CoV-2* / immunology
  • Spike Glycoprotein, Coronavirus* / immunology

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • BNT162 Vaccine